Terms: = Prostate cancer AND IL7R, P16871, IL-7R-alpha, CDW127, CD127, ENSG00000168685, 3575 AND Treatment
11 results:
1. Adverse health outcomes among rural prostate cancer survivors: A population-based study.
Huang D; Chang CE; Newman M; Deshmukh V; Snyder J; Date A; Galvao C; Lloyd S; Henry NL; O'Neil B; Hashibe M
Cancer Epidemiol; 2023 Oct; 86():102430. PubMed ID: 37473579
[TBL] [Abstract] [Full Text] [Related]
2. A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents.
Leigh J; Qureshi D; Sucha E; Mahdavi R; Kushnir I; Lavallée LT; Bosse D; Webber C; Tanuseputro P; Ong M
Cancer Med; 2023 Mar; 12(5):5569-5579. PubMed ID: 36397730
[TBL] [Abstract] [Full Text] [Related]
3. IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer Eradication in a preclinical model.
Wang D; Shao Y; Zhang X; Lu G; Liu B
J Transl Med; 2020 Jan; 18(1):23. PubMed ID: 31937346
[TBL] [Abstract] [Full Text] [Related]
4. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
[TBL] [Abstract] [Full Text] [Related]
6. Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial.
Guttilla A; Bortolus R; Giannarini G; Ghadjar P; Zattoni F; Gnech M; Palumbo V; Valent F; Garbeglio A; Zattoni F
Radiat Oncol; 2014 Jan; 9():24. PubMed ID: 24423462
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of circulating regulatory T cells (CD4+CD25+cd127-) after cryosurgery in prostate cancer.
Si TG; Wang JP; Guo Z
Asian J Androl; 2013 Jul; 15(4):461-5. PubMed ID: 23728588
[TBL] [Abstract] [Full Text] [Related]
8. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.
Derhovanessian E; Adams V; Hähnel K; Groeger A; Pandha H; Ward S; Pawelec G
Int J Cancer; 2009 Sep; 125(6):1372-9. PubMed ID: 19533748
[TBL] [Abstract] [Full Text] [Related]
9. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
[TBL] [Abstract] [Full Text] [Related]
10. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma.
Ambrus JL; Dembinski W; Ambrus JL; Sykes DE; Akhter S; Kulaylat MN; Islam A; Chadha KC
Cancer; 2003 Dec; 98(12):2730-3. PubMed ID: 14669296
[TBL] [Abstract] [Full Text] [Related]
11. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract] [Full Text] [Related]
